Boxer Capital
Latest statistics and disclosures from Boxer Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SWTX, CYTK, RVMD, TYRA, APLS, and represent 32.63% of Boxer Capital's stock portfolio.
- Added to shares of these 10 stocks: FATE (+$57M), NKTX (+$45M), VKTX (+$25M), KURA (+$21M), ALLO (+$17M), RNA (+$16M), SANA (+$16M), PSTX (+$14M), ENGN (+$12M), THRD (+$12M).
- Started 13 new stock positions in ENGN, BOLD, ALLO, PSTX, KURA, SANA, LABD, VKTX, JSPR, IPSC. AMLX, ABSI, ATRA.
- Reduced shares in these 10 stocks: Mirati Therapeutics (-$188M), , Karuna Therapeutics Ord (-$79M), ARGX (-$24M), IOVA (-$9.6M), IMVT (-$5.7M), KOD, Rain Therapeutics, KALV, BCEL.
- Sold out of its positions in BCEL, ImmunoGen, Karuna Therapeutics Ord, KOD, Mirati Therapeutics, Rain Therapeutics.
- Boxer Capital was a net seller of stock by $-112M.
- Boxer Capital has $2.0B in assets under management (AUM), dropping by 0.92%.
- Central Index Key (CIK): 0001465837
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Boxer Capital
Boxer Capital holds 59 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Springworks Therapeutics (SWTX) | 8.3 | $168M | 3.4M | 49.22 |
|
|
Cytokinetics Com New (CYTK) | 7.3 | $147M | 2.1M | 70.11 |
|
|
Revolution Medicines (RVMD) | 6.8 | $138M | 4.3M | 32.23 |
|
|
Tyra Biosciences (TYRA) | 5.2 | $106M | 6.4M | 16.40 |
|
|
Apellis Pharmaceuticals (APLS) | 5.0 | $102M | 1.7M | 58.78 |
|
|
Ideaya Biosciences (IDYA) | 4.8 | $97M | 2.2M | 43.88 |
|
|
Merus N V (MRUS) | 4.2 | $86M | 1.9M | 45.03 |
|
|
Sarepta Therapeutics (SRPT) | 4.2 | $84M | 650k | 129.46 |
|
|
Nuvalent Inc-a (NUVL) | 4.2 | $84M | 1.1M | 75.09 |
|
|
BeiGene Sponsored Adr (BGNE) | 3.9 | $78M | 500k | 156.39 |
|
|
Tango Therapeutics (TNGX) | 3.2 | $65M | 8.2M | 7.94 |
|
|
Nkarta (NKTX) | 3.0 | $61M | +289% | 5.6M | 10.81 |
|
Fate Therapeutics (FATE) | 3.0 | $60M | +1543% | 8.2M | 7.34 |
|
Avidity Biosciences Ord (RNA) | 2.2 | $44M | +54% | 1.7M | 25.52 |
|
Akero Therapeutics (AKRO) | 2.1 | $42M | 1.7M | 25.26 |
|
|
Rocket Pharmaceuticals (RCKT) | 2.0 | $40M | 1.5M | 26.94 |
|
|
Argenx SE Sponsored Adr (ARGX) | 1.9 | $39M | -37% | 100k | 393.72 |
|
Legend Biotech Corp Sponsored Ads (LEGN) | 1.7 | $34M | 600k | 56.09 |
|
|
Axsome Therapeutics (AXSM) | 1.6 | $32M | 400k | 79.80 |
|
|
Arcus Biosciences Incorporated (RCUS) | 1.5 | $30M | 1.6M | 18.88 |
|
|
Anaptysbio Inc Common (ANAB) | 1.4 | $29M | 1.3M | 22.52 |
|
|
Immunovant (IMVT) | 1.3 | $27M | -17% | 825k | 32.31 |
|
Xenon Pharmaceuticals (XENE) | 1.3 | $26M | 600k | 43.05 |
|
|
Arvinas Ord (ARVN) | 1.2 | $25M | 609k | 41.28 |
|
|
Iteos Therapeutics (ITOS) | 1.2 | $25M | 1.8M | 13.64 |
|
|
Viking Therapeutics (VKTX) | 1.2 | $25M | NEW | 300k | 82.00 |
|
Oric Pharmaceuticals (ORIC) | 1.2 | $24M | 1.7M | 13.75 |
|
|
Kura Oncology (KURA) | 1.1 | $21M | NEW | 1.0M | 21.33 |
|
Geron Corporation (GERN) | 1.0 | $20M | +100% | 6.0M | 3.30 |
|
Day One Biopharmaceuticals I (DAWN) | 1.0 | $20M | 1.2M | 16.52 |
|
|
Third Harmonic Bio (THRD) | 0.9 | $19M | +166% | 2.0M | 9.44 |
|
Kalvista Pharmaceuticals (KALV) | 0.9 | $19M | -3% | 1.6M | 11.86 |
|
Allogene Therapeutics (ALLO) | 0.8 | $17M | NEW | 3.9M | 4.47 |
|
Structure Therapeutics Sponsored Ads (GPCR) | 0.8 | $17M | 400k | 42.86 |
|
|
Prothena Corp SHS (PRTA) | 0.8 | $17M | +3% | 690k | 24.77 |
|
Sana Biotechnology (SANA) | 0.8 | $16M | NEW | 1.5M | 10.00 |
|
Relay Therapeutics (RLAY) | 0.7 | $15M | 1.8M | 8.30 |
|
|
Poseida Therapeutics I (PSTX) | 0.7 | $14M | NEW | 4.5M | 3.19 |
|
Engene Holdings (ENGN) | 0.6 | $12M | NEW | 728k | 16.95 |
|
Prelude Therapeutics (PRLD) | 0.6 | $12M | 2.6M | 4.74 |
|
|
Enliven Therapeutics (ELVN) | 0.6 | $12M | +3% | 671k | 17.59 |
|
Iovance Biotherapeutics (IOVA) | 0.5 | $11M | -46% | 750k | 14.82 |
|
Jasper Therapeutics Com New (JSPR) | 0.5 | $10M | NEW | 350k | 29.36 |
|
Boundless Bio (BOLD) | 0.5 | $10M | NEW | 711k | 14.25 |
|
Spyre Therapeutics Com New (SYRE) | 0.5 | $9.5M | 250k | 37.93 |
|
|
Century Therapeutics (IPSC) | 0.4 | $7.3M | NEW | 1.8M | 4.18 |
|
Zentalis Pharmaceuticals (ZNTL) | 0.4 | $7.1M | 450k | 15.76 |
|
|
Amylyx Pharmaceuticals (AMLX) | 0.2 | $4.3M | NEW | 1.5M | 2.84 |
|
Absci Corp (ABSI) | 0.2 | $4.0M | NEW | 700k | 5.68 |
|
Atara Biotherapeutics (ATRA) | 0.1 | $2.9M | NEW | 4.2M | 0.69 |
|
Black Diamond Therapeutics (BDTX) | 0.1 | $2.6M | 506k | 5.07 |
|
|
Direxion SHS ETF TR Daily S&p Biotec (LABD) | 0.1 | $2.6M | NEW | 350k | 7.29 |
|
Bioatla (BCAB) | 0.1 | $2.4M | 686k | 3.44 |
|
|
Health Sciences Acq Corp 2 (OBIO) | 0.1 | $1.3M | 238k | 5.27 |
|
|
Protara Therapeutics Com Stk (TARA) | 0.0 | $839k | 209k | 4.01 |
|
|
Milestone Pharmaceuticals (MIST) | 0.0 | $553k | 309k | 1.79 |
|
|
DBV Technologies S A Sponsored Adr | 0.0 | $375k | 500k | 0.75 |
|
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $81k | 267k | 0.30 |
|
|
Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $2.2k | 67k | 0.03 |
|
Past Filings by Boxer Capital
SEC 13F filings are viewable for Boxer Capital going back to 2015
- Boxer Capital 2024 Q1 filed May 15, 2024
- Boxer Capital 2023 Q4 filed Feb. 14, 2024
- Boxer Capital 2023 Q3 filed Nov. 14, 2023
- Boxer Capital 2023 Q2 filed Aug. 14, 2023
- Boxer Capital 2023 Q1 filed May 15, 2023
- Boxer Capital 2022 Q4 filed Feb. 14, 2023
- Boxer Capital 2022 Q3 filed Nov. 14, 2022
- Boxer Capital 2022 Q2 filed Aug. 15, 2022
- Boxer Capital 2022 Q1 filed May 16, 2022
- Boxer Capital 2021 Q4 filed Feb. 14, 2022
- Boxer Capital 2021 Q3 filed Nov. 15, 2021
- Boxer Capital 2021 Q2 filed Aug. 16, 2021
- Boxer Capital 2021 Q1 filed May 17, 2021
- Boxer Capital 2020 Q4 filed Feb. 16, 2021
- Boxer Capital 2020 Q3 restated filed Nov. 17, 2020
- Boxer Capital 2020 Q3 filed Nov. 16, 2020